Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Peter Lindsay Anderson

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-6128
    Other Positions
    TitleDirector-Faculty
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    DepartmentSOP-Administration


    Collapse Research 
    Collapse research activities and funding
    R01AI064029     (ANDERSON, PETER LINDSAY)Mar 15, 2005 - Feb 28, 2011
    NIH/NIAID
    Sex and disease dependent nucleoside analog toxicity
    Role: Principal Investigator

    R03AI068438     (ANDERSON, PETER LINDSAY)Jul 15, 2006 - Jun 30, 2009
    NIH/NIAID
    Genetic-determinants of protease inhibitor pharmacology
    Role: Principal Investigator

    R34AI078776     (ANDERSON, PETER LINDSAY)May 1, 2008 - Apr 30, 2009
    NIH/NIAID
    Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis
    Role: Principal Investigator

    S10RR023442     (ANDERSON, PETER LINDSAY)Sep 30, 2008 - Sep 29, 2009
    NIH/NCRR
    UPLC-MS for pharmacology studies in HIV
    Role: Principal Investigator

    U01AI084735     (ANDERSON, PETER LINDSAY)Aug 15, 2009 - Jul 31, 2014
    NIH/NIAID
    Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis
    Role: Principal Investigator

    U01AI106499     (ANDERSON, PETER LINDSAY)Apr 15, 2013 - Mar 31, 2017
    NIH/NIAID
    PrEP and ART adherence monitoring using dried blood spots
    Role: Principal Investigator

    R01AI122298     (ANDERSON, PETER L.)Dec 1, 2015 - Nov 30, 2020
    NIH/NIAID
    Novel approaches for quantitative assessment of adherence
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ellsworth GB, Burke LA, Wells MT, Mishra S, Caffrey M, Liddle D, Madhava M, O'Neal C, Anderson PL, Bushman L, Ellison L, Stein J, Gulick RM. Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. J Acquir Immune Defic Syndr. 2021 Jan 01; 86(1):73-80. PMID: 33306564.
      View in: PubMed
    2. Stranix-Chibanda L, Anderson PL, Kacanek D, Hosek S, Huang S, Nematadzira TG, Taulo F, Korutaro V, Nakabiito C, Masenya M, Lypen K, Brown E, Ibrahim ME, Yager J, Wiesner L, Johnston B, Amico KR, Rooney JF, Chakhtoura N, Spiegel HML, Chi BH. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in sub-Saharan Africa. Clin Infect Dis. 2020 Dec 20. PMID: 33341883.
      View in: PubMed
    3. Mann SC, Morrow M, Coyle RP, Coleman SS, Saderup A, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL, Castillo-Mancilla JR. Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. J Acquir Immune Defic Syndr. 2020 Dec 01; 85(4):483-488. PMID: 33136749.
      View in: PubMed
    4. Ibrahim ME, Castillo-Mancilla JR, Yager J, Brooks KM, Bushman L, Saba L, Kiser JJ, MaWhinney S, Anderson PL. Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. AIDS Res Hum Retroviruses. 2020 Nov 15. PMID: 33191774.
      View in: PubMed
    5. Brooks KM, Castillo-Mancilla JR, Morrow M, MaWhinney S, Blum J, Wyles DL, Rowan SE, Ibrahim ME, Zheng JH, Johnson B, Gomez J, Choi YJ, Cendali F, Haas H, Roon L, Bushman LR, Anderson PL, Kiser JJ. Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. J Antimicrob Chemother. 2020 Nov 01; 75(11):3303-3310. PMID: 32766700.
      View in: PubMed
    6. Pons-Faudoa FP, Trani ND, Sizovs A, Shelton KA, Momin Z, Bushman LR, Xu J, Lewis DE, Demaria S, Hawkins T, Rooney JF, Marzinke MA, Kimata JT, Anderson PL, Nehete PN, Arduino RC, Sastry KJ, Grattoni A. Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics. 2020 Oct 17; 12(10). PMID: 33080776.
      View in: PubMed
    7. Vernon F, Morrow M, MaWhinney S, Coyle R, Coleman S, Ellison L, Zheng JH, Bushman L, Kiser JJ, Galárraga O, Anderson PL, Castillo-Mancilla J. Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa391. PMID: 33072812.
      View in: PubMed
    8. von Kleist M, García-Lerma JG, Liu A, Anderson PL. Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV. Front Pharmacol. 2020; 11:1288. PMID: 32982729.
      View in: PubMed
    9. Grant RM, Pellegrini M, Defechereux PA, Anderson PL, Yu M, Glidden DV, O'Neal J, Yager J, Bhasin S, Sevelius J, Deutsch MB. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the iBrEATHe Study. Clin Infect Dis. 2020 Aug 08. PMID: 32766890.
      View in: PubMed
    10. Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Curr HIV/AIDS Rep. 2020 08; 17(4):301-314. PMID: 32424549.
      View in: PubMed
    11. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 07 25; 396(10246):239-254. PMID: 32711800.
      View in: PubMed
    12. Spinelli MA, Lowery B, Shuford JA, Spindler J, Kearney MF, McFarlane JR, McDonald C, Okochi H, Phung N, Kuncze K, Jee K, Johannessen D, Anderson PL, Smith DK, Defechereux P, Grant RM, Gandhi M. Use of Drug-Level Testing and Single-Genome Sequencing to Unravel a Case of HIV Seroconversion on PrEP. Clin Infect Dis. 2020 Jul 20. PMID: 32686825.
      View in: PubMed
    13. Sizovs A, Pons-Faudoa FP, Malgir G, Shelton KA, Bushman LR, Chua CYX, Anderson PL, Nehete PN, Sastry KJ, Grattoni A. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. Int J Pharm. 2020 Sep 25; 587:119623. PMID: 32663582.
      View in: PubMed
    14. Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. . 2020 Jul 01; 84(3):323-330. PMID: 32539288.
      View in: PubMed
    15. Leech AA, Biancarelli D, Aaron E, Miller ES, Coleman JS, Anderson PL, Nkwihoreze H, Condron B, Sullivan M. HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. AIDS Patient Care STDS. 2020 07; 34(7):295-302. PMID: 32639209.
      View in: PubMed
    16. Coyle RP, Morrow M, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL, Castillo-Mancilla JR. Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV. J Antimicrob Chemother. 2020 06 01; 75(6):1591-1598. PMID: 32211787.
      View in: PubMed
    17. Yager JL, Anderson PL. Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Expert Opin Drug Metab Toxicol. 2020 Jun; 16(6):463-474. PMID: 32250177.
      View in: PubMed
    18. Lee SS, Anderson PL, Kwan TH, Lui GCY, Chan DPC, Wong NS, Lee KCK, Lam TTN. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion. Int J Infect Dis. 2020 May; 94:41-43. PMID: 32173577.
      View in: PubMed
    19. Pintye J, Kinuthia J, Abuna F, Mugwanya K, Lagat H, Dettinger JC, Odinga D, Sila J, Anderson PL, John-Stewart G, Baeten JM. Frequency and predictors of tenofovir-diphosphate detection among young Kenyan women in a real-world pre-exposure prophylaxis implementation program. Clin Infect Dis. 2020 Feb 28. PMID: 32109293.
      View in: PubMed
    20. Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clin Infect Dis. 2020 02 03; 70(4):687-691. PMID: 31179503.
      View in: PubMed
    21. Pu F, Pandey S, Bushman LR, Anderson PL, Ouyang Z, Cooks RG. Correction to: Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Anal Bioanal Chem. 2020 02; 412(6):1465. PMID: 31953716.
      View in: PubMed
    22. Pu F, Pandey S, Bushman LR, Anderson PL, Ouyang Z, Cooks RG. Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Anal Bioanal Chem. 2020 Feb; 412(6):1243-1249. PMID: 31897555.
      View in: PubMed
    23. Liu SN, Gufford BT, Lu JBL, Bushman LR, Anderson PL, Bergstrom RF, Desta Z, Gupta SK. Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis. Clin Pharmacol Ther. 2020 May; 107(5):1200-1208. PMID: 31675437.
      View in: PubMed
    24. Coyle RP, Schneck CD, Morrow M, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL, Castillo-Mancilla JR. Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. AIDS Behav. 2019 Dec; 23(12):3493-3502. PMID: 30798457.
      View in: PubMed
    25. Child J, Chen X, Mistry RD, Somme S, MacBrayne C, Anderson PL, Jones RN, Parker SK. Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. J Pediatric Infect Dis Soc. 2019 Sep 25; 8(4):297-302. PMID: 29788329.
      View in: PubMed
    26. Marins LMS, Torres TS, Leite IDC, Moreira RI, Luz PM, Hoagland B, Kallas EG, Madruga JV, Liu AY, Anderson PL, Grinsztejn B, Veloso VG. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. PLoS One. 2019; 14(8):e0221281. PMID: 31430318.
      View in: PubMed
    27. Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364. PMID: 31081036.
      View in: PubMed
    28. Brooks KM, Ibrahim ME, Castillo-Mancilla JR, MaWhinney S, Alexander K, Tilden S, Kerr BJ, Ellison L, McHugh C, Bushman LR, Kiser JJ, Hosek S, Huhn GD, Anderson PL. Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. J Antimicrob Chemother. 2019 08 01; 74(8):2352-2359. PMID: 31093649.
      View in: PubMed
    29. Castillo-Mancilla JR, Coyle RP, Coleman SS, Morrow M, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL. Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV. AIDS Res Hum Retroviruses. 2020 03; 36(3):173-175. PMID: 31204866.
      View in: PubMed
    30. Morrow M, MaWhinney S, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Anderson PL, Castillo-Mancilla JR. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. J Infect Dis. 2019 07 19; 220(4):635-642. PMID: 30942881.
      View in: PubMed
    31. Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke MA, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo N, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. Lancet HIV. 2019 08; 6(8):e498-e508. PMID: 31320290.
      View in: PubMed
    32. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG, Buchbinder SP, Grant RM. Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Res Hum Retroviruses. 2019 09; 35(9):788-793. PMID: 31119944.
      View in: PubMed
    33. Spinelli MA, Glidden DV, Anderson PL, Gandhi M, Cohen S, Vittinghoff E, Coleman ME, Scott H, Bacon O, Elion R, Kolber MA, Buchbinder SP, Liu AY. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. . 2019 06 01; 81(2):158-162. PMID: 31095005.
      View in: PubMed
    34. Hoenigl M, Hassan A, Moore DJ, Anderson PL, Corado K, Dubé MP, Ellorin EE, Blumenthal J, Morris SR. Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. . 2019 06 01; 81(2):166-174. PMID: 30865175.
      View in: PubMed
    35. Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, Anderson PL, Lester R, Andrew E, Estes I, Serrano P, Brothers J, Buchbinder S, Hosek S, Fuchs JD. Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Clin Infect Dis. 2019 05 30; 68(12):2010-2017. PMID: 30239620.
      View in: PubMed
    36. Frasca K, Morrow M, Coyle RP, Coleman SS, Ellison L, Bushman LR, Kiser JJ, Zheng JH, Mawhinney S, Anderson PL, Castillo-Mancilla J. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. J Antimicrob Chemother. 2019 05 01; 74(5):1395-1401. PMID: 30668713.
      View in: PubMed
    37. Castillo-Mancilla JR, Morrow M, Coyle RP, Coleman SS, Gardner EM, Zheng JH, Ellison L, Bushman LR, Kiser JJ, Mawhinney S, Anderson PL. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Clin Infect Dis. 2019 04 08; 68(8):1335-1342. PMID: 30137238.
      View in: PubMed
    38. Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, Anderson PL, Bolan R, Jordan WC, Rooney JF, Wohl AR, Landovitz RJ. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care. 2019 10; 31(10):1228-1233. PMID: 30894013.
      View in: PubMed
    39. Liu AY, Zhang J, Anderson PL, Wagner T, Pan Z, Peda M, Gomez K, Beamer M, Jacobson C, Strizki J, Dezzutti CS, Piper JM. Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. Clin Infect Dis. 2019 03 19; 68(7):1129-1135. PMID: 30289444.
      View in: PubMed
    40. Hoesley CJ, Chen BA, Anderson PL, Dezzutti CS, Strizki J, Sprinkle C, Heard F, Bauermeister J, Hall W, Jacobson C, Berthiaume J, Mayo A, Gundacker H, Richardson-Harman N, Piper J. Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings. Clin Infect Dis. 2019 03 19; 68(7):1136-1143. PMID: 30289435.
      View in: PubMed
    41. McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. AIDS. 2019 02 01; 33(2):237-246. PMID: 30557160.
      View in: PubMed
    42. Hoenigl M, Morgan E, Franklin D, Anderson PL, Pasipanodya E, Dawson M, Hanashiro M, Ellorin EE, Blumenthal J, Heaton R, Moore DJ, Morris SR. Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. J Neurovirol. 2019 06; 25(3):324-330. PMID: 30617849.
      View in: PubMed
    43. Yager JL, Coyle RP, Coleman SS, Ellison L, Zheng JH, Bushman L, Gardner EM, Morrow M, MaWhinney S, Anderson PL, Justice Kiser J, Castillo-Mancilla JR. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. J Int Assoc Provid AIDS Care. 2019 Jan-Dec; 18:2325958219888457. PMID: 31750768.
      View in: PubMed
    44. Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, Corado K, Blumenthal JS, Daar ES, Milam J, Dubé MP, Morris S. Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerg Infect Dis. 2018 12; 24(12). PMID: 30457536.
      View in: PubMed
    45. Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M. Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV. 2018 Nov 29. PMID: 30503324.
      View in: PubMed
    46. Havens PL, Tamhane A, Stephensen CB, Schuster GU, Gordon CM, Liu N, Wilson CM, Hosek SG, Anderson PL, Kapogiannis BG, Mulligan K. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. AIDS Res Hum Retroviruses. 2019 02; 35(2):123-128. PMID: 30280906.
      View in: PubMed
    47. Innes S, van der Laan L, Anderson PL, Cotton M, Denti P. Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. Antimicrob Agents Chemother. 2018 11; 62(11). PMID: 30104267.
      View in: PubMed
    48. Koss CA, Liu AY, Castillo-Mancilla J, Bacchetti P, McHugh C, Kuncze K, Morrow M, Louie A, Seifert S, Okochi H, MaWhinney S, Gandhi M, Anderson PL. Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring. AIDS. 2018 09 24; 32(15):2189-2194. PMID: 30212404.
      View in: PubMed
    49. Anderson PL. What Can Urine Tell Us About Medication Adherence? EClinicalMedicine. 2018 Aug-Sep; 2-3:5-6. PMID: 31193677.
      View in: PubMed
    50. Ibrahim ME, Brooks KM, Castillo-Mancilla JR, McHugh C, Morrow M, Brothers J, MaWhinney S, Hosek S, Huhn G, Anderson PL. Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. AIDS Res Hum Retroviruses. 2018 10; 34(10):835-837. PMID: 30047286.
      View in: PubMed
    51. Brooks KM, Anderson PL. Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention. Clin Pharmacol Ther. 2018 12; 104(6):1056-1059. PMID: 30178462.
      View in: PubMed
    52. Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. AIDS. 2018 08 24; 32(13):1891-1898. PMID: 29894385.
      View in: PubMed
    53. Chua CYX, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, Gao S, Di Trani N, Susnjar A, Shelton K, Bushman LR, Folci M, Filgueira CS, Marzinke MA, Anderson PL, Hu M, Nehete P, Arduino RC, Sastry JK, Grattoni A. Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. J Control Release. 2018 09 28; 286:315-325. PMID: 30092254.
      View in: PubMed
    54. MacBrayne CE, Marks KM, Fierer DS, Naggie S, Chung RT, Hughes MD, Kim AY, Peters MG, Brainard DM, Seifert SM, Castillo-Mancilla JR, Bushman LR, Anderson PL, Kiser JJ. Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. J Antimicrob Chemother. 2018 08 01; 73(8):2112-2119. PMID: 29746648.
      View in: PubMed
    55. Hughes SM, Ferre AL, Yandura SE, Shetler C, Baker CAR, Calienes F, Levy CN, Astronomo RD, Shu Z, Lentz GM, Fialkow M, Kirby AC, McElrath MJ, Sinclair E, Rohan LC, Anderson PL, Shacklett BL, Dezzutti CS, Gao D, Hladik F. Cryopreservation of human mucosal tissues. PLoS One. 2018; 13(7):e0200653. PMID: 30059507.
      View in: PubMed
    56. Monte AA, West K, McDaniel KT, Flaten HK, Saben J, Shelton S, Abdelmawla F, Bushman LR, Williamson K, Abbott D, Anderson PL. CYP2D6 Genotype Phenotype Discordance Due to Drug-Drug Interaction. Clin Pharmacol Ther. 2018 11; 104(5):933-939. PMID: 29882961.
      View in: PubMed
    57. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis. 2018 07 18; 67(3):411-419. PMID: 29415175.
      View in: PubMed
    58. Ren Y, Zhang W, Lin Z, Bushman LR, Anderson PL, Ouyang Z. In-capillary microextraction for direct mass spectrometry analysis of biological samples. Talanta. 2018 Nov 01; 189:451-457. PMID: 30086946.
      View in: PubMed
    59. Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH. Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clin Infect Dis. 2018 05 17; 66(11):1712-1721. PMID: 29420695.
      View in: PubMed
    60. Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL. Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. . 2018 03 01; 77(3):295-298. PMID: 29189417.
      View in: PubMed
    61. Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018 03; 5(3):e136-e145. PMID: 29467098.
      View in: PubMed
    62. Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. . 2018 02 01; 77(2):193-198. PMID: 28991887.
      View in: PubMed
    63. Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY. Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PLoS One. 2018; 13(1):e0190118. PMID: 29315307.
      View in: PubMed
    64. Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M. Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2018 01 06; 66(2):213-219. PMID: 29020194.
      View in: PubMed
    65. Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother. 2018 01; 62(1). PMID: 29038282.
      View in: PubMed
    66. Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, Anderson PL, Flynn R, Lee DP, Bolan RK, Jordan WC, Tseng CH, Dierst-Davies R, Rooney J, Wohl AR. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. . 2017 12 15; 76(5):501-511. PMID: 28902074.
      View in: PubMed
    67. Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H. Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. . 2017 12 01; 76(4):e104-e106. PMID: 29076941.
      View in: PubMed
    68. Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS. 2017 Oct 23; 31(16):2245-2251. PMID: 28832411.
      View in: PubMed
    69. Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2018 02; 5(2):e68-e78. PMID: 28986029.
      View in: PubMed
    70. Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. . 2017 10 01; 76(2):177-182. PMID: 28639995.
      View in: PubMed
    71. Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, Kootstra NA, Anderson PL, Reiss P, de Vries HJC, Prins JM, de Bree GJ. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV. 2017 11; 4(11):e522-e528. PMID: 28919303.
      View in: PubMed
    72. Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E. Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. AIDS. 2017 07 31; 31(12):1709-1714. PMID: 28700394.
      View in: PubMed
    73. Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH. Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. . 2017 07 01; 75(3):271-279. PMID: 28328548.
      View in: PubMed
    74. Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. J Int AIDS Soc. 2017 04 06; 20(1):21472. PMID: 28418232.
      View in: PubMed
    75. Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL. Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opin Drug Metab Toxicol. 2017 Jun; 13(6):641-650. PMID: 28335648.
      View in: PubMed
    76. Knox DC, Anderson PL, Harrigan PR, Tan DH. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. N Engl J Med. 2017 02 02; 376(5):501-502. PMID: 28146652.
      View in: PubMed
    77. Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clin Infect Dis. 2017 Feb 01; 64(3):317-325. PMID: 28013265.
      View in: PubMed
    78. Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS One. 2016; 11(11):e0165505. PMID: 27832147.
      View in: PubMed
    79. Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother. 2016 11; 60(11):6692-6697. PMID: 27572401.
      View in: PubMed
    80. Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother. 2017 02; 72(2):478-485. PMID: 28073964.
      View in: PubMed
    81. Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ, Gardner EM, Macatangay BJ, Breen EC, Jacobson LP, Anderson PL, Wada NI. Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. Clin Infect Dis. 2016 Dec 15; 63(12):1661-1667. PMID: 27660234.
      View in: PubMed
    82. Chen X, McAllister KJ, Klein B, Bushman LR, Anderson PL. Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate. Biomed Chromatogr. 2017 Mar; 31(3). PMID: 27557296.
      View in: PubMed
    83. Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL. Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses. 2016 Oct/Nov; 32(10-11):981-991. PMID: 27526873.
      View in: PubMed
    84. Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ. A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells. Pharm Res. 2017 01; 34(1):73-83. PMID: 27633886.
      View in: PubMed
    85. Glidden DV, Anderson PL, Grant RM. Pharmacology supports on-demand PrEP. Lancet HIV. 2016 09; 3(9):e405-e406. PMID: 27562738.
      View in: PubMed
    86. Chen X, Castillo-Mancilla JR, Seifert SM, McAllister KB, Zheng JH, Bushman LR, MaWhinney S, Anderson PL. Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother. 2016 09; 60(9):5387-92. PMID: 27353267.
      View in: PubMed
    87. Anderson PL, Reirden D, Castillo-Mancilla J. Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. . 2016 08 15; 72 Suppl 3:S230-4. PMID: 27429188.
      View in: PubMed
    88. Wong TC, Lan A, Kiser JJ, Anderson PL, Patel K, Tillman H, Naggie S. Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. Hepatology. 2016 09; 64(3):999-1000. PMID: 26799354.
      View in: PubMed
    89. Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC. A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. AIDS. 2016 Mar 13; 30(5):743-51. PMID: 26605514.
      View in: PubMed
    90. Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18. PMID: 26892777.
      View in: PubMed
    91. Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, Guida LA, Kiser JJ, Bushman LR, Anderson PL. Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J Pharm Biomed Anal. 2016 Apr 15; 122:16-20. PMID: 26829517.
      View in: PubMed
    92. Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM. Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clin Infect Dis. 2016 May 01; 62(9):1172-7. PMID: 26797207.
      View in: PubMed
    93. Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Intern Med. 2016 Jan; 176(1):75-84. PMID: 26571482.
      View in: PubMed
    94. Anderson PL, García-Lerma JG, Heneine W. Nondaily preexposure prophylaxis for HIV prevention. Curr Opin HIV AIDS. 2016 Jan; 11(1):94-101. PMID: 26633641.
      View in: PubMed
    95. Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016 Jan; 32(1):32-43. PMID: 26414912.
      View in: PubMed
    96. Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ. Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. Antimicrob Agents Chemother. 2015 Dec; 59(12):7671-9. PMID: 26416874.
      View in: PubMed
    97. Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. J Infect Dis. 2015 Dec 15; 212(12):1988-95. PMID: 26071566.
      View in: PubMed
    98. Meditz AL, Palmer C, Predhomme J, Searls K, Kerr B, Seifert S, Caraway P, Gardner EM, MaWhinney S, Anderson PL. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. AIDS Res Hum Retroviruses. 2015 Oct; 31(10):1015-22. PMID: 26059647.
      View in: PubMed
    99. Bjornstad P, Anderson PL, Maahs DM. Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. Acta Diabetol. 2016 Apr; 53(2):331-3. PMID: 25959420.
      View in: PubMed
    100. Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2015 Aug 15; 61(4):572-80. PMID: 25908682.
      View in: PubMed
    101. Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM. Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. J Infect Dis. 2015 Nov 01; 212(9):1402-6. PMID: 25895984.
      View in: PubMed
    102. Castillo-Mancilla JR, Meditz A, Wilson C, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL. Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals. . 2015 Apr 15; 68(5):495-501. PMID: 25763783.
      View in: PubMed
    103. Wu LS, Rower JE, Burton JR, Anderson PL, Hammond KP, Baouchi-Mokrane F, Everson GT, Urban TJ, D'Argenio DZ, Kiser JJ. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015 Apr; 59(4):2179-88. PMID: 25645847.
      View in: PubMed
    104. Baxi SM, Liu A, Bacchetti P, Mutua G, Sanders EJ, Kibengo FM, Haberer JE, Rooney J, Hendrix CW, Anderson PL, Huang Y, Priddy F, Gandhi M. Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures. . 2015 Jan 01; 68(1):13-20. PMID: 25296098.
      View in: PubMed
    105. Jimmerson LC, Ray ML, Bushman LR, Anderson PL, Klein B, Rower JE, Zheng JH, Kiser JJ. Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC-MS/MS quantification. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 26; 978-979:163-72. PMID: 25555148.
      View in: PubMed
    106. Liu A, Glidden DV, Anderson PL, Amico KR, McMahan V, Mehrotra M, Lama JR, MacRae J, Hinojosa JC, Montoya O, Veloso VG, Schechter M, Kallas EG, Chariyalerstak S, Bekker LG, Mayer K, Buchbinder S, Grant R. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. . 2014 Dec 15; 67(5):528-37. PMID: 25230290.
      View in: PubMed
    107. Castillo-Mancilla JR, Searls K, Caraway P, Zheng JH, Gardner EM, Predhomme J, Bushman LR, Anderson PL, Meditz AL. Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women. AIDS Res Hum Retroviruses. 2015 Apr; 31(4):428-32. PMID: 25328112.
      View in: PubMed
    108. Seifert SM, Glidden DV, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Rower C, Klein B, Kerr BJ, Guida LA, Zheng JH, Bushman LR, Anderson PL. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men. Clin Infect Dis. 2015 Mar 01; 60(5):804-10. PMID: 25409469.
      View in: PubMed
    109. Amico KR, Marcus JL, McMahan V, Liu A, Koester KA, Goicochea P, Anderson PL, Glidden D, Guanira J, Grant R. Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection. . 2014 Aug 15; 66(5):530-7. PMID: 24853306.
      View in: PubMed
    110. Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, Hosek S, Mosquera C, Casapia M, Montoya O, Buchbinder S, Veloso VG, Mayer K, Chariyalertsak S, Bekker LG, Kallas EG, Schechter M, Guanira J, Bushman L, Burns DN, Rooney JF, Glidden DV. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014 Sep; 14(9):820-9. PMID: 25065857.
      View in: PubMed
    111. Maahs DM, Bushman L, Kerr B, Ellis SL, Pyle L, McFann K, Bouffard A, Bishop FK, Nguyen N, Anderson PL. A practical method to measure GFR in people with type 1 diabetes. J Diabetes Complications. 2014 Sep-Oct; 28(5):667-73. PMID: 25027389.
      View in: PubMed
    112. Anderson PL, Glidden DV, Bushman LR, Heneine W, García-Lerma JG. Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. J Antimicrob Chemother. 2014 Sep; 69(9):2470-6. PMID: 24862094.
      View in: PubMed
    113. Chen X, Bushman LR, McAllister KJ, Anderson PL, Kiser JJ. Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma. Biomed Chromatogr. 2014 Dec; 28(12):1714-21. PMID: 24760592.
      View in: PubMed
    114. Liegler T, Abdel-Mohsen M, Bentley LG, Atchison R, Schmidt T, Javier J, Mehrotra M, Eden C, Glidden DV, McMahan V, Anderson PL, Li P, Wong JK, Buchbinder S, Guanira JV, Grant RM. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014 Oct 15; 210(8):1217-27. PMID: 24740633.
      View in: PubMed
    115. Czaja CA, Levin A, Moridani M, Krank JL, Curran-Everett D, Anderson PL. Cefoxitin continuous infusion for lung infection caused by the Mycobacterium abscessus group. Antimicrob Agents Chemother. 2014 Jun; 58(6):3570-1. PMID: 24733469.
      View in: PubMed
    116. Liu AY, Yang Q, Huang Y, Bacchetti P, Anderson PL, Jin C, Goggin K, Stojanovski K, Grant R, Buchbinder SP, Greenblatt RM, Gandhi M. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736. PMID: 24421901.
      View in: PubMed
    117. Jimmerson LC, Zheng JH, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 01; 944:18-24. PMID: 24291608.
      View in: PubMed
    118. Zheng JH, Guida LA, Rower C, Castillo-Mancilla J, Meditz A, Klein B, Kerr BJ, Langness J, Bushman L, Kiser J, Anderson PL. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2014 Jan; 88:144-51. PMID: 24055850.
      View in: PubMed
    119. Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013 May; 9(5):573-88. PMID: 23514375.
      View in: PubMed
    120. Ghodke Y, Anderson PL, Sangkuhl K, Lamba J, Altman RB, Klein TE. PharmGKB summary: zidovudine pathway. Pharmacogenet Genomics. 2012 Dec; 22(12):891-4. PMID: 22960662.
      View in: PubMed
    121. Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013 Feb; 29(2):384-90. PMID: 22935078.
      View in: PubMed
    122. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012 Sep 12; 4(151):151ra125. PMID: 22972843.
      View in: PubMed
    123. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8. PMID: 22331658.
      View in: PubMed
    124. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1227-34. PMID: 22394315.
      View in: PubMed
    125. Rower JE, Meditz A, Gardner EM, Lichtenstein K, Predhomme J, Bushman LR, Klein B, Zheng JH, Mawhinney S, Anderson PL. Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine. Antimicrob Agents Chemother. 2012 Jun; 56(6):3011-9. PMID: 22391541.
      View in: PubMed
    126. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012 Nov; 52(11):1725-38. PMID: 22174437.
      View in: PubMed
    127. Bushman LR, Kiser JJ, Rower JE, Klein B, Zheng JH, Ray ML, Anderson PL. Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011 Sep 10; 56(2):390-401. PMID: 21715120.
      View in: PubMed
    128. Rower JE, Klein B, Bushman LR, Anderson PL. Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomed Chromatogr. 2012 Jan; 26(1):12-20. PMID: 21465499.
      View in: PubMed
    129. Wempe MF, Anderson PL. Atazanavir metabolism according to CYP3A5 status: an in vitro-in vivo assessment. Drug Metab Dispos. 2011 Mar; 39(3):522-7. PMID: 21148251.
      View in: PubMed
    130. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb; 66(2):240-50. PMID: 21118913.
      View in: PubMed
    131. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30; 363(27):2587-99. PMID: 21091279.
      View in: PubMed
    132. Enomoto L, Anderson PL, Li S, Edelstein CL, Weinberg A. Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):47-55. PMID: 20929390.
      View in: PubMed
    133. Kiser JJ, Bumpass JB, Meditz AL, Anderson PL, Bushman L, Ray M, Predhomme JA, Rower J, Mawhinney S, Brundage R. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010 Dec; 54(12):4999-5003. PMID: 20921313.
      View in: PubMed
    134. Anderson PL, Rower JE. Zidovudine and Lamivudine for HIV Infection. Clin Med Rev Ther. 2010; 2:a2004. PMID: 20953318.
      View in: PubMed
    135. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov; 64(5):1071-9. PMID: 19710077.
      View in: PubMed
    136. McRae M, Clay PG, Anderson PL, Glaros AG. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. Pharmacotherapy. 2009 Aug; 29(8):937-42. PMID: 19637947.
      View in: PubMed
    137. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009 Jun 01; 23(9):1035-46. PMID: 19381075.
      View in: PubMed
    138. Anderson PL, King T, Zheng JH, MaWhinney S. Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. J Antimicrob Chemother. 2008 Oct; 62(4):738-45. PMID: 18567572.
      View in: PubMed
    139. Anderson PL. Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Curr Opin HIV AIDS. 2008 May; 3(3):258-65. PMID: 19372976.
      View in: PubMed
    140. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. . 2008 Mar 01; 47(3):298-303. PMID: 18398970.
      View in: PubMed
    141. Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007 Sep 12; 21(14):1849-54. PMID: 17721092.
      View in: PubMed
    142. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008 Feb; 83(2):265-72. PMID: 17597712.
      View in: PubMed
    143. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR. Atazanavir-containing renal calculi in an HIV-infected patient. AIDS. 2007 May 11; 21(8):1060-2. PMID: 17457108.
      View in: PubMed
    144. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. . 2006 Aug 01; 42(4):441-9. PMID: 16791115.
      View in: PubMed
    145. King T, Bushman L, Kiser J, Anderson PL, Ray M, Delahunty T, Fletcher CV. Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 07; 843(2):147-56. PMID: 16828350.
      View in: PubMed
    146. Anderson PL, Kakuda TN. Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother. 2006 Jul; 58(1):220-1. PMID: 16717052.
      View in: PubMed
    147. Aquilante CL, Langaee TY, Anderson PL, Zineh I, Fletcher CV. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clin Chim Acta. 2006 Oct; 372(1-2):195-8. PMID: 16701601.
      View in: PubMed
    148. Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006 Apr; 26(4):511-4. PMID: 16553510.
      View in: PubMed
    149. Kiser JJ, Anderson PL, Kakuda TN. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Expert Opin Pharmacother. 2006 Feb; 7(2):229-41. PMID: 16433587.
      View in: PubMed
    150. King T, Bushman L, Anderson PL, Delahunty T, Ray M, Fletcher CV. Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 02; 831(1-2):248-57. PMID: 16412710.
      View in: PubMed
    151. Kiser JJ, Anderson PL, Gerber JG. Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs. Curr HIV/AIDS Rep. 2005 Jun; 2(2):61-7. PMID: 16091250.
      View in: PubMed
    152. Anderson PL. The ABC's of pharmacokinetics. Posit Aware. 2005; Spec No:4-7, 19. PMID: 15828101.
      View in: PubMed
    153. Kakuda TN, Anderson PL, Becker SL. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS. 2004 Dec 03; 18(18):2442-4. PMID: 15622326.
      View in: PubMed
    154. Anderson PL. Pharmacologic perspectives for once-daily antiretroviral therapy. Ann Pharmacother. 2004 Nov; 38(11):1924-34. PMID: 15479772.
      View in: PubMed
    155. Anderson PL, Fletcher CV. Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. Curr HIV/AIDS Rep. 2004 Apr; 1(1):33-9. PMID: 16091221.
      View in: PubMed
    156. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004 Mar 01; 38(5):743-53. PMID: 14986261.
      View in: PubMed
    157. Anderson PL, Miller S, Bushman LR. Stability of zidovudine with oxytocin in a simulated Y-site injection. Am J Health Syst Pharm. 2004 Feb 15; 61(4):394-6. PMID: 15011769.
      View in: PubMed
    158. Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003 Oct 17; 17(15):2159-68. PMID: 14523272.
      View in: PubMed
    159. Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clin Pharmacol Ther. 2002 Apr; 71(4):280-5. PMID: 11956511.
      View in: PubMed
    160. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002 Mar 08; 16(4):551-60. PMID: 11872998.
      View in: PubMed
    161. Anderson PL, Fletcher CV. Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors. Curr Infect Dis Rep. 2001 Aug; 3(4):381-387. PMID: 11470030.
      View in: PubMed
    162. Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother. 2001 Jan; 45(1):236-42. PMID: 11120972.
      View in: PubMed
    163. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV. Indinavir plasma protein binding in HIV-1-infected adults. AIDS. 2000 Oct 20; 14(15):2293-7. PMID: 11089617.
      View in: PubMed
    164. Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000 Sep 29; 14(14):2137-44. PMID: 11061655.
      View in: PubMed
    165. Anderson PL, Noormohamed SE, Henry K, Brundage RC, Balfour HH, Fletcher CV. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy. 2000 Aug; 20(8):917-22. PMID: 10939552.
      View in: PubMed
    166. Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Saf. 2000 Aug; 23(2):131-42. PMID: 10945375.
      View in: PubMed
    167. Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 2000 Jun; 30 Suppl 2:S151-9. PMID: 10860900.
      View in: PubMed
    168. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS. 1999 Nov 12; 13(16):2311-2. PMID: 10563722.
      View in: PubMed
    169. Cohen SP, Anderson PL. Mucoid impaction following nasal intubation in a child with an upper respiratory infection. J Clin Anesth. 1998 Jun; 10(4):327-30. PMID: 9667350.
      View in: PubMed
    170. Strom TB, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion proteins. Ann N Y Acad Sci. 1991 Dec 30; 636:233-50. PMID: 1793213.
      View in: PubMed
    171. Strom TB, Anderson PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion proteins. Semin Immunol. 1990 Nov; 2(6):467-79. PMID: 2104283.
      View in: PubMed
    Anderson's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)